VIRAX HOLDINGS LIMITED(VHL)

name changed to Prescient Therapeutics Limited

The securities of Virax Holdings Limited (the "Company") will be reinstated to official quotation at the commencement of trading on Tuesday, 19 November 2013 following effectuation of the deed of company arrangement and completion of a capital raising. Security Code: VHL

releases Annual Report for the Year Ended 30 June 2013, Half Yearly Report for the period ended 31 December 2012 and Annual Report for the Year Ended 30 June 2012

company is no longer in administration

in accordance with the Prospectus dated 19 September 2013, the Company has had significant interest in the capital raising and has received subscriptions well in excess of the proposed maximum $2,500,000 capital raising

issues a prospectus for the offer of 25 million First Placement Shares at an issue price of $0.00001 per Share to raise $250 and 100 million First Placement Options at an issue price of $0.00001 per First Placement Option to raise $1,000 (together the First Placement) and For the offer of a minimum of 360,000,000 Second Placement Shares and up to a maximum of 140,000,000 additional Second Placement Shares, at an issue price of $0.005 per Share to raise at least $1,800,000 or up to a maximum of $2,500,000

it is our understanding a share consolidation is about to take place whereby 10 existing shares are consolidated into one share

executes a reconstruction deed

the company is to enter into a Deed of Company Arrangement

Directors today appointed Mr. Laurie A Fitzgerald and Mr. Stephen R Dixon of Grant Thornton as Voluntary Administrators of the Company

The directors of the Company request the continuation of the suspension of the Company's securities from official quotation. The Company is to make an announcement shortly concerning the termination of the Share Sale Agreement with the vendors of 4G Vaccines Pty Ltd

provides an update on Transgene" clinical program TG4001 (HPV therapeutic vaccine). This project utilises Co-X-GeneTM technology and is the subject of a license agreement between Transgene and Virax

at the Noteholder General Meeting of Virax Holdings Limited the resolutions to amend to terms of the Convertible Notes were passed

releases copies of the Notice of Meeting, Proxy Form and Information Memorandum for the Noteholder General Meeting to be held on Friday 30 March 2012 at Quest Beaumont Kew, 7 Studley Park Road, Kew at 2.00 pm - ASX Code - VHLG

suspended following failure to lodge financial reports

the unsecured convertible notes (the "Notes") of Virax Holdings Limited (the "Company") will be suspended from quotation at the close of trading on 21 December 2011, pending their maturity on 31 December 2011. For details of a proposal to extend the maturity date of the Notes to 31 March 2012, please refer to the Company's notice of meeting lodged on ASX on 12 December 2011. Security Code: VHLG Please note the suspension only applies to the Notes and not to the Company's other quoted securities

name changed from Rancoo Limited